BVT Put 130 NVO 18.10.2024/ DE000VC1AFW1 /
10/16/2024 8:52:20 AM | Chg.+0.19 | Bid10:00:33 PM | Ask10:00:33 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.13EUR | +20.21% | - Bid Size: - |
- Ask Size: - |
Novo Nordisk | 130.00 USD | 10/18/2024 | Put |
Newsfile Corp
8/28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
8/28
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
8/28
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
GlobeNewswire
8/27
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
8/26
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amy...
GlobeNewswire
8/21
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
GlobeNewswire
8/14
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. Georg...
GlobeNewswire
8/6
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
8/1
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Dire...
GlobeNewswire
7/11
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansio...
GlobeNewswire
7/11
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...
GlobeNewswire
7/11
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...